CONKO-001

Background

Phase III RCT (CONKO-001). 368 patients with resected pancreatic cancer (R0 or R1) after macroscopically complete resection. Randomized to adjuvant gemcitabine ×6 cycles or observation. Pivotal trial establishing gemcitabine as standard adjuvant chemotherapy.

Interventions and follow up

Arm A: Gemcitabine 1,000 mg/m² days 1, 8, 15 every 28 days ×6 cycles
Arm B: Observation (surgery alone)
Primary endpoint: Disease-free survival
Median follow-up: 136 months (11+ years)

Results

mDFS: 13.4 vs 6.9 months, HR 0.55, P<.001
mOS (initial 2007 JAMA): 22.8 vs 20.2 months, P=.005
5-yr OS (2013 JAMA): 20.7% vs 10.4%, HR 0.76, P=.01
10-yr OS: 12.2% vs 7.7%

Adverse events

Hematologic: Grade ≥3 leukopenia 4%, thrombocytopenia 1% with gemcitabine.
Overall: Gemcitabine generally well tolerated; no treatment-related deaths.

Conclusions

Adjuvant gemcitabine significantly improved DFS and long-term OS versus observation after resection. The ~10% 5-year OS benefit (20.7% vs 10.4%) established gemcitabine as standard-of-care adjuvant therapy for over a decade.

Key Limitations

The initial 2007 analysis showed only modest OS benefit (2.6 months); 11 years of follow-up were needed for meaningful survival curve separation. ~30% of patients had R1 resections, complicating interpretation of curatively resected outcomes. No quality-of-life data. Did not compare with 5-FU-based or combination regimens (later addressed by ESPAC-3, ESPAC-4, PRODIGE-24).

Clinical Context

CONKO-001 established gemcitabine as standard adjuvant therapy for resected pancreatic cancer, replacing 5-FU/LV after ESPAC-1. ESPAC-4 later showed gemcitabine + capecitabine superior to gemcitabine alone, and PRODIGE-24 showed mFOLFIRINOX superior to gemcitabine in fit patients. Gemcitabine monotherapy remains appropriate for PS 1-2 or elderly patients unable to tolerate intensified regimens (per ESMO guidance).

References

References: Oettle H et al, JAMA 2013 (CONKO-001 long-term) | Oettle H et al, JAMA 2007 (CONKO-001 initial)